Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating on the shares. The firm noted its acquisition ...

Canaccord raised the firm’s price target on Nevro (NVRO) to $5.85 from $4 and keeps a Hold rating on the shares. The firm noted Globus Medical ...

Nevro (NVRO) shares ended the last trading session 13.9% higher at $5.72. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares ...

Piper Sandler analyst Adam Maeder upgraded shares of Nevro Corp (NYSE:NVRO), a medical device company with a market ...

NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask: When was the last time you recovered money for shareholders?

Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. to Globus Medical for $5.85 per share is fair to Nevro shareholders. Halper Sadeh encourages Nevro ...

Ademi & Fruchter LLP is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical.

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.

Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical ...

Detailed price information for Envirogold Global Ltd (NVRO-CN) from The Globe and Mail including charting and trades.